Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Journal of Research in Pharmacy
2022 , Vol 26 , Issue 3
Development and Assessment of Mitoxantrone and 4- Methyl Umbelliferone Nanoemulsions for Chemotherapeutic Potential on MCF-7 Cell Line
1Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh2Delhi Institute of Pharmaceutical Education and Research, New Delhi
3Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh
4Gurukula Kangri Vishwavidyalaya, Department of Pharmaceutical Sciences, Haridwar, Uttarakhand, India DOI : 10.29228/jrp.144 Every year, millions of new cases of cancer of various forms are identified, resulting in a high mortality rate. For the management of breast cancers, chemotherapeutics such as Mitoxantrone (MTO) and 4-Methyl Umbelliferone(4-MU), show significant cytotoxic effects. The goal of this research was to develop and characterize nanoemulsion of MTO and 4-MU and to further assess the cytotoxic activity of this formulation against MCF-7 cell lines using MTT assay. Aqueous microtitration technique was employed to prepare the nanoemulsion using cinnamaldehyde as an oil phase, Tween-80 as a surfactant, and PEG-400 as a co-surfactant. The developed nanoemulsions were characterized for droplet size, PDI, %transmittance, drug content, surface morphology, and in vitro release. Photomicrograph of developed NE showed spherical droplets with a mean diameter of 113.2±5.3 nm and 123.2±6.17 nm for 4-MU and MTO, respectively, and a PDI was found to be 0.254 and 0.281 for 4-MU and MTO respectively. Approximately 78.53±4.61 % of 4-MU were released under sink conditions after 8 hours in a dissolution study. MTO-NE and 4-MU-NE had a longer drug release profile in the in-vitro method when compared to standard drug solutions. The cytotoxic effect of 4-MU and 4-MU-NE was assessed on the MCF-7 cell line by MTT assay and exhibited IC50s of 3.868 mM and 1.885 Mm against MCF-7, respectively. MTO and MTO-NE had IC50s of 10.51μM and 5.027 μM against MCF-7, respectively. The results of this study show the great potential of the prepared nanoemulsions for breast cancer; hence it can be concluded that developed NEs of chemotherapeutics lead the way forward for further in-vivo research. Keywords : Mitoxantrone; 4-methyl umbelliferone; Nanoemulsion; MCF-7 cell line; MTT Assay